Chimeric Antigen Receptor News and Research

RSS

Leukemia-on-a-chip offers breakthrough in personalized cancer treatment

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could transform how blood cancer treatments are tested and tailored for patients.

2 Jul 2025

Next generation CAR-T cells push the boundaries of lymphoma treatment

CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic landscape of lymphoma.

23 Jun 2025

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

15 Jun 2025

Boosting CAR T cell survival to improve solid tumor therapy

Chimeric Antigen Receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.

13 Jun 2025

Eva1 targeted CAR T cells successfully eliminate tumors in preclinical study

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors.

11 Jun 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30 May 2025

Pitt professor wins NSF CAREER Award for AI-driven immunotherapy research

The University of Pittsburgh's Natasa Miskov-Zivanov, assistant professor of electrical and computer engineering, has received a prestigious Faculty Early Career Development (CAREER) Award of $581,503 from the National Science Foundation (NSF) for her project titled "Artificial Intelligence-Driven Framework for Efficient and Explainable Immunotherapy Design."

30 May 2025

Innovative technology simplifies T cell harvesting for cancer immunotherapy

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers like lymphoma and leukemia and shows promise against solid tumors.

29 May 2025

NUS researchers develop breakthrough gene delivery technology for immune cells

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently delivers genetic material into human immune cells.

26 May 2025

Nectin4-targeted VHH-CAR-T cells show potency against bladder cancer

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

29 Apr 2025

New CAR T cell therapy shows promise for treating advanced thyroid cancer

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, according to researchers from The University of Texas MD Anderson Cancer Center.

29 Apr 2025

Novel cancer immunotherapy approach could complement existing CAR-T treatments

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

24 Apr 2025

Calibr-Skaggs receives FDA approval to test sCAR-T therapy in patients with autoimmune diseases

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.

9 Apr 2025

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring.

2 Apr 2025

HLA-DRB1 molecule can be a potential target in treating acute myeloid leukemia

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells.

1 Apr 2025

New tool helps predict CAR T therapy outcomes for lymphoma patients

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation's top 5 cancer centers by U.S. News & World Report, and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published today in Nature Medicine.

1 Apr 2025

Development of lymphoma following CAR-T cell therapy

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

22 Feb 2025

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science.

20 Feb 2025

Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children with neuroblastoma, with one patient remaining cancer-free for over 18 years.

17 Feb 2025